Epilepsy Research
Epilepsy is a group of neurological conditions consisting of recurrent, usually unprovoked epileptic seizures. Epileptic seizures have recently been defined as "a transient occurrence of signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain". Epilepsy is one of the most common disorders of the brain, with one in 10 people suffering at least one seizure in their lifetime. There are over 40 different types of epilepsy, each of which presents with its own unique combination of seizure type, typical age of onset, EEG findings, treatment, and prognosis.
Epilepsy Research Products Targets
- NHE (3)
- Monocarboxylate Transporter (3)
- VEGFR (16)
- FGFR (5)
- Voltage-gated Sodium (NaV) Channel (30)
- Voltage-gated Potassium (KV) Channel (38)
- Voltage-gated Calcium Channel (CaV) (38)
- Others (13)
- Epithelial Sodium Channel (3)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- Gap Channel (7)
- Trk Receptor (13)
- Acid-Sensing Ion Channel (3)
- Calcium-Activated Potassium (KCa) Channel (19)
- Inward Rectifier Potassium (Kir) Channel (21)
- Sodium and Potassium ATPase (3)
- KCC2 (1)
- H+-ATPase (3)
- H+,K+-ATPase (4)
- Chloride Channel (17)
- NCX (5)
- Ca2+-ATPase (7)
- NKCC (2)
- Cytokine (15)
Products for Epilepsy Research - Page 40
- Cat.No. Product Name Information/Activity
-
BCC7936
VU 29
890764-36-0
-
BCC6969
(2R,4R)-APDC
(2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluRs) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects.
-
BCC6609
L-CCG-l
117857-93-9
-
BCC5691
DCG IV
DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1/5R=389/630 μM) and III receptors (IC50: mGlu4/6/7/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects.
-
BCC7614
LY 354740
Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.
-
BCC7368
LY 379268
Highly selective group II mGlu agonist
-
BCC7623
(±)-LY 395756
852679-66-4
-
BCC6758
MAP4
157381-42-5
-
BCC6925
(RS)-APICA
170847-18-4
-
BCC6871
EGLU
EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent.


